Dexamethasone/Pancreatic Clamp P & F
Conditions: Insulin Resistance; Prediabetic State; Non-Alcoholic Fatty Liver Disease; Overweight and Obesity Interventions: Drug: Insulin human; Drug: Octreotide Acetate; Drug: Glucagon; Drug: Human Growth Hormone; Drug: Dexamethasone Oral; Other: [6,6-2H2] D-glucose; Drug: 20% D-glucose (aq); Dietary Supplement: BOOST Plus; Device: Harvard Apparatus PHD ULTRA CP syringe pump; Device: Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer; Other: Normal saline; Other: Human albumin Sponsors: Columbia University; Albert Einstein College of Medicine; National Institute of Diabetes and Digestive and Kidne...
Source: ClinicalTrials.gov - November 10, 2023 Category: Research Source Type: clinical trials
A Single-dose Study of Octreotide Injection in Healthy Adult Subjects
Condition: Acromegaly Interventions: Drug: SYHX2008 injection; Drug: Octreotide Acetate Microspheres for Injection injection; Drug: Sandostatin ® injection; Drug: Placebo to SYHX2008 injection Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 9, 2023 Category: Research Source Type: clinical trials
A Single-dose Study of Octreotide Injection in Healthy Adult Subjects
Condition: Acromegaly Interventions: Drug: SYHX2008 injection; Drug: Octreotide Acetate Microspheres for Injection injection; Drug: Sandostatin ® injection; Drug: Placebo to SYHX2008 injection Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 9, 2023 Category: Research Source Type: clinical trials
A Single-dose Study of Octreotide Injection in Healthy Adult Subjects
Condition: Acromegaly Interventions: Drug: SYHX2008 injection; Drug: Octreotide Acetate Microspheres for Injection injection; Drug: Sandostatin ® injection; Drug: Placebo to SYHX2008 injection Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 9, 2023 Category: Research Source Type: clinical trials
Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation
Conditions: Neuroendocrine Tumors; Carcinoid Syndrome Intervention: Drug: Sandostatin Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain Terminated (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2019 Category: Research Source Type: clinical trials
